Lupin’s US arm recalls 12,888 bottles of ulcer drug in US
Lupin’s US arm is recalling 12,888 bottles of Famotidine for oral suspension used in treatment of ulcers from the American market
New Delhi: Drug firm Lupin’s US arm, Lupin Pharmaceuticals Inc, is recalling 12,888 bottles of Famotidine for oral suspension used in treatment of ulcers from the American market.
The reason for the recall is current Good Manufacturing Practise (CGMP) deviations, United States Food and Drug Administration (US FDA) said in its latest Enforcement Report.
Lupin Pharmaceuticals Inc is recalling 12,888 bottles of Famotidine for oral suspension USP, 40 mg/5 ml, 50 ml bottle, manufactured by Lupin Ltd at its Goa facility, it added. The ongoing nation wide voluntary recall is a class III recall, the report said.
Famotidine for oral suspension is indicated in short-term treatment of active duodenal ulcer, active benign gastric ulcer and gastroesophageal reflux disease.
As per the US FDA, a class III recall is initiated in “a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.
- What night lights reveal about the Indian economy
- Aadhaar has emerged as key document for new bank accounts: Survey
- Motherson Sumi plans to invest Rs2,000 crore this fiscal to build new capacities
- Paytm says never shared users’ data with third-parties, government
- Four years of Modi govt: Labour reforms slow down despite policy revamp
Editor's Picks »
- Motherson Sumi continues to face margin pressure in foreign markets
- What the Warren Buffett indicator tells us about market valuations today
- Jet Airways lands with a thud in Q4 as fuel costs increase
- IBC amendments: Some dilutions, and a lot more speed
- Patanjali’s gambit is paying off in toothpaste wars